Prediction of Response to Hormone Therapy in Prostate Cancer by Bromodeoxyuridine Labeling

这是非常有益的，以预测癌症的药物治疗，如前列腺癌的激素治疗或膀胱癌或肾癌的化疗的疗效。在治疗前和治疗后的泌尿系恶性肿瘤组织中测量溴脱氧尿苷（BrdU）的标记指数，BrdU是细胞中DNA合成的标记物。为此，我们开发了一种新的装置，用于标记组织与BrdU。该装置由注射器和容器组成，使得体外标记组织比以前更容易和更迅速。前列腺癌13例，膀胱癌10例，肾癌2例。所有前列腺癌患者激素治疗后标记指数均明显下降。4例患者的标记指数大于2%，但其他许多患者未显示标记细胞。4例患者中有3例出现疾病进展或早期复发。另一方面，没有标记细胞的患者没有复发或进展。由于本系列病例数量非常有限，因此在膀胱癌或肾癌方面没有显著发现。

It is very beneficial to predict the efficacy of medical treatments for cancer such as the hormone treatment for prostate cancer or the chemotherapy for bladder or renal cancer. The labeling index of bromodeoxyuridine (BrdU), which is a marker of DNA synthesis in cells, was measured both before and after the treatment in tissues of urological malignancies. For this purpose we developed a new device for labeling tissues with BrdU. The device, composed of a syringe and a container, made it possible to labeling the tissue in vitro easier and more promptly than before. Thirteen patients with prostate cancer, 10 with bladder cancer and 2 with renal cancer were examined. In all the prostate cancer patients, the labeling index was much decreased after the hormone treatment. Four patients showed the labeling indexes greater than 2 per cents although many of others showed no labeled cells. Three of the 4 patients encountered progression or early relapse of the disease. On the other hand, patients with no labeling cells had no recurrence or progression.There were no significant findings on bladder cancer or renal cancer because the number of cases in this series was very limited.